The preceding three pharmacology modules have established the mechanistic and clinical profiles of each major antihypertensive drug class. This module synthesizes that knowledge into a practical treatment framework: how to initiate therapy, when and how to combine agents, which evidence-based regimens produce the best outcomes, how to individualize treatment across key patient subgroups, and how to approach the patient whose blood pressure remains uncontrolled despite multiple agents.
A thorough understanding of this framework is the bridge between knowing how individual drugs work and being able to manage hypertension effectively across the full breadth of clinical practice.1,2
The decision to initiate pharmacotherapy and the choice of initial agent are determined by four converging factors: BP stage, total cardiovascular risk, the presence of compelling indications, and patient-specific characteristics including age, race and ethnicity, comorbidities, tolerability, and cost.1,2 The fundamental principle is that BP reduction per se accounts for the majority of cardiovascular benefit with antihypertensive therapy. For each 10 mmHg reduction in systolic BP, stroke risk is reduced by approximately 35%, coronary artery disease risk by approximately 20%, heart failure risk by approximately 28%, and all-cause mortality by approximately 13%.3 This dose-response relationship between BP reduction and cardiovascular risk provides the rationale for combination therapy: achieving larger reductions in BP through complementary mechanisms produces proportionally greater cardiovascular benefit, typically exceeding what any single agent can achieve at tolerable doses.
The traditional stepped-care approach of starting with one drug and adding a second if needed has been largely superseded by evidence favoring earlier combination therapy for most patients.1,2 Most patients with Stage 2 hypertension (BP 140/90 mmHg or above) require at least two drugs to reach target BP; initiating one agent delays achievement of target by months to years. Combination therapy at half-standard doses of each agent achieves BP reduction equivalent to full-dose monotherapy with fewer adverse effects, because dose-response curves for adverse effects are steeper than for efficacy. Single-pill combinations substantially improve adherence, which is a major driver of real-world treatment failure, and early intensive BP control reduces total cardiovascular event burden more effectively than delayed control.
Monotherapy may be appropriate in Stage 1 hypertension (130–139/80–89 mmHg) with low cardiovascular risk (10-year ASCVD risk below 10%); in elderly or frail patients at high risk of adverse effects from rapid BP reduction such as orthostatic hypotension, falls, and acute kidney injury; and in patients who are close to target BP, only 5–10 mmHg above goal.
ACC/AHA 2017 and ESH 2023 guidance aligns on the following approach: Stage 1 hypertension with low risk warrants lifestyle modification first, with pharmacotherapy if target is not met in 3–6 months. Stage 1 hypertension with high risk (10-year ASCVD risk 10% or above, established cardiovascular disease, chronic kidney disease, or diabetes) requires initiation of pharmacotherapy alongside lifestyle modification. Stage 2 hypertension calls for pharmacotherapy, with combination therapy if BP is 20/10 mmHg or more above target, initiated simultaneously with lifestyle modification.1,2
Lifestyle interventions lower BP independently and enhance the efficacy of antihypertensive drugs. They should be prescribed alongside pharmacotherapy at all stages.1 The Dietary Approaches to Stop Hypertension (DASH) dietary pattern reduces systolic BP by approximately 11 mmHg in hypertensive patients, through a diet high in fruits, vegetables, low-fat dairy, whole grains, and nuts, and low in saturated fat, sodium, red meat, and sweets.4 Dietary sodium restriction to below 2.3 g per day reduces systolic BP approximately 5–6 mmHg, with greater effect in salt-sensitive individuals including the elderly, Black patients, and those with chronic kidney disease. Weight loss reduces systolic BP by approximately 1 mmHg per kilogram lost. Aerobic exercise of 90–150 minutes per week of moderate intensity reduces systolic BP approximately 5–8 mmHg. Alcohol moderation to two or fewer standard drinks per day for men and one or fewer for women reduces systolic BP approximately 4 mmHg. Smoking cessation does not directly lower resting BP but dramatically reduces total cardiovascular risk and is essential for comprehensive risk management.
Effective combination therapy pairs agents that act through complementary and non-redundant mechanisms, counteract each other's compensatory neurohormonal responses, and do not share the same adverse effect profile, or where one agent mitigates the adverse effects of another. The core complementary mechanisms in hypertension treatment are renin-angiotensin-aldosterone system (RAAS) suppression through ACE inhibitors (ACEi) or ARBs, which reduces vasoconstriction, aldosterone, and sodium retention driven by angiotensin II; volume reduction through diuretics, which reduces intravascular volume and resets the pressure-natriuresis curve while activating the RAAS (which is then counteracted by the RAAS inhibitor, producing mutual enhancement); vasodilation through calcium channel blockers (CCBs), which directly reduces peripheral arteriolar resistance independently of neurohormonal pathways and is effective even in low-renin states; and sympathetic suppression through beta-blockers, which reduces cardiac output and renin release and is additive to RAAS inhibition and diuresis in high-sympathetic-tone states.
The CCB plus RAAS inhibitor combination is the preferred dual regimen for most patients. The ACCOMPLISH trial (2008) randomized 11,506 high-risk hypertensive patients to benazepril plus amlodipine versus benazepril plus hydrochlorothiazide (HCTZ); benazepril plus amlodipine reduced composite cardiovascular events by a 20% relative risk reduction despite similar achieved BP in both arms.5 The physiological synergy is bidirectional: RAAS inhibition blunts reflex RAAS activation from CCB-induced vasodilation, and RAAS inhibition also reduces CCB-induced peripheral edema by causing venodilation and efferent arteriolar dilation. This combination is the preferred foundation for triple therapy in high-risk patients.
The RAAS inhibitor plus thiazide or thiazide-like diuretic combination is well-established; diuretic activation of the RAAS enhances RAAS inhibitor efficacy, while the RAAS inhibitor blunts diuretic-induced hypokalemia and metabolic effects. The combination of CCB plus thiazide diuretic produces additive antihypertensive effect through complementary non-interacting mechanisms and is suitable when RAAS inhibition is contraindicated or not tolerated, such as in bilateral renal artery stenosis (RAS), prior angioedema, or pregnancy.
Triple therapy combining a CCB, RAAS inhibitor, and thiazide or thiazide-like diuretic is the standard of care for hypertension uncontrolled on dual therapy. It addresses all three major BP-regulating pathways: vasoconstriction (RAAS), fluid volume (diuretic), and direct vascular tone (CCB). Both NICE guidelines and ACC/AHA guidelines identify this as the preferred first-choice triple combination,1,2 and the majority of patients who require triple therapy can be controlled on this regimen when doses are optimized.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT, 2002) randomized 33,357 high-risk hypertensive patients to chlorthalidone, amlodipine, lisinopril, or doxazosin (the doxazosin arm was terminated early).6 Chlorthalidone, amlodipine, and lisinopril produced equivalent reductions in the primary composite endpoint of fatal coronary heart disease or nonfatal myocardial infarction. Chlorthalidone was superior to lisinopril for stroke, heart failure, and combined cardiovascular events. Chlorthalidone was equivalent to amlodipine overall, while amlodipine was slightly superior for stroke in Black patients. The clinical implication is that thiazide-type diuretics and CCBs are robust first-line options, with chlorthalidone as the preferred thiazide.
The SPRINT trial (2015) randomized 9,361 patients with cardiovascular risk of 15% or above or age 75 or above to an intensive systolic BP target below 120 mmHg versus a standard target below 140 mmHg.7 Intensive control reduced the composite cardiovascular event rate by 25% and all-cause mortality by 27%, but serious adverse events were higher in the intensive group, including acute kidney injury, syncope, and electrolyte abnormalities. An important caveat is that SPRINT used automated unattended office BP measurement, which yields readings approximately 5–10 mmHg lower than standard attended measurement, meaning SPRINT's 120 mmHg target approximates 130 mmHg by standard measurement. The trial excluded patients with diabetes and prior stroke, and the mean number of antihypertensive medications in the intensive group was 2.8, confirming that combination therapy is the rule rather than the exception for intensive BP control.
The ONTARGET trial (2008) compared telmisartan versus ramipril versus their combination in high cardiovascular risk patients.8 It provided definitive evidence against the ACEi plus ARB combination, known as dual RAAS blockade: no additional benefit over monotherapy was observed, with significantly more acute kidney injury, hyperkalemia, and hypotension. Telmisartan was non-inferior to ramipril with better tolerability.
Single-pill combinations have transformed adherence in hypertension management. Adherence rates with single-pill combinations are 20–30% higher than with separate pills across multiple studies and meta-analyses.1,2 Common and evidence-supported single-pill combinations include ACEi or ARB plus CCB (lisinopril/amlodipine, perindopril/amlodipine, valsartan/amlodipine, telmisartan/amlodipine), ACEi or ARB plus thiazide (lisinopril/HCTZ, valsartan/HCTZ, losartan/HCTZ, olmesartan/HCTZ), and triple combinations including perindopril/amlodipine/indapamide, which are increasingly available.
Single-pill combinations should be initiated at low dose when combination therapy is indicated from the outset, preferred over separate pills whenever clinically equivalent agents are available in combined form, and an exception is made during the initial period when dose titration requires individual adjustments of each component, after which reversion to a single-pill combination is appropriate once doses are stable.
The concept of compelling indications refers to conditions in which a specific drug class provides outcome benefit independent of BP reduction, and this concept is central to individualized prescribing.1,2 In heart failure with reduced ejection fraction (HFrEF), first-line guideline-directed medical therapy (GDMT) includes ACEi or ARB or sacubitril/valsartan, one of three beta-blockers with proven HFrEF mortality benefit (carvedilol, metoprolol succinate, bisoprolol), a mineralocorticoid receptor antagonist (MRA) such as spironolactone or eplerenone, and an sodium-glucose cotransporter 2 (SGLT2) inhibitor. Non-dihydropyridine (DHP) CCBs should be avoided due to negative inotropy, while DHP CCBs such as amlodipine are safe and can be used for BP control. Target BP is below 130/80 mmHg. Post-myocardial infarction management prioritizes a beta-blocker for rate control, remodeling prevention, and sudden death prevention, along with an ACEi or ARB particularly with left ventricular dysfunction or anterior myocardial infarction, and an MRA if ejection fraction is below 40% or diabetes is present. Non-DHP CCBs should be avoided if left ventricular dysfunction is present.
In stable coronary artery disease, beta-blockers provide anti-ischemic benefit by reducing myocardial oxygen demand, while long-acting DHP CCBs such as amlodipine provide anti-ischemic benefit with CAMELOT trial support, and ACEi or ARB therapy provides secondary prevention evidence from the HOPE and EUROPA trials. A caution applies regarding the J-curve: diastolic BP below 65–70 mmHg may reduce coronary perfusion in patients with established coronary artery disease, and over-aggressive lowering should be avoided. In atrial fibrillation, rate control is provided by beta-blockers or non-DHP CCBs, which should not be combined due to heart block risk. Antithrombotic therapy is determined separately by the CHA2DS2-VASc score and is not an antihypertensive decision.
Hypertension management in diabetes and in chronic kidney disease is covered in dedicated modules (HTN-08 and HTN-07 respectively). In brief, first-line therapy in both conditions is an ACEi or ARB for renoprotection, with CCBs and low-dose thiazides as appropriate additions. SGLT2 inhibitors and GLP-1 receptor agonists carry additional antihypertensive and cardiorenal outcome benefits. High-dose thiazides should be avoided due to glucose intolerance, and if a beta-blocker is required, nebivolol or carvedilol are preferred. The BP target is below 130/80 mmHg in both conditions.
Younger patients below 40–50 years often have high-renin, high-sympathetic-tone hypertension, making RAAS inhibitors and beta-blockers particularly effective. Secondary causes should be excluded in patients with onset before age 30 without obesity or family history. Fertility and pregnancy planning must be considered: ACEi and ARBs should be avoided in women who may become pregnant, and contraception should be discussed. In middle-aged patients between 50 and 65 years, the standard four-drug framework applies with individualization by comorbidity. Metabolic syndrome is common in this group, favoring RAAS inhibitors plus CCBs and avoidance of high-dose thiazides and non-selective beta-blockers. Screening for subclinical target organ damage including left ventricular hypertrophy, microalbuminuria, carotid intima-media thickness, and coronary calcium score is appropriate.
In elderly patients aged 65 years or above, CCBs and thiazide-like diuretics are highly effective and well-tolerated, with DHP CCBs preferred for isolated systolic hypertension. ACEi and ARBs remain appropriate with compelling indications. Beta-blockers are less effective for isolated systolic hypertension and should be reserved for patients with compelling indications such as HFrEF, post-MI, or atrial fibrillation. The guiding principle is to start low and go slow, titrating over weeks to months, with monitoring for orthostatic hypotension, falls, cognitive effects, and electrolyte disturbances. In the very elderly aged 80 or above, the HYVET trial supports active treatment with indapamide with or without perindopril; targets should be individualized and frailty assessment should guide treatment intensity.
Black patients have a disproportionately higher prevalence and severity of hypertension, typically characterized by a lower renin state with reduced RAAS activity, higher salt sensitivity, and a predominantly volume-dependent hypertension. The most effective initial agents are CCBs and thiazide-type diuretics.6 ACEi and ARBs are less effective as monotherapy in Black patients but achieve equivalent efficacy when combined with a diuretic or CCB and remain appropriate with compelling indications such as chronic kidney disease, HFrEF, or diabetes. Black patients have a higher incidence of ACEi-associated angioedema at three to four times the rate observed in white patients. In ALLHAT, chlorthalidone and amlodipine produced superior cardiovascular outcomes compared to lisinopril in Black patients,6 and combination therapy from the outset is especially important in this group.
NSAIDs reduce the efficacy of ACEi, ARBs, and diuretics, increase the risk of acute kidney injury when combined with RAAS inhibitors, and raise BP by 3–5 mmHg on average. Substituting acetaminophen whenever possible is appropriate. Oral contraceptives activate the RAAS through hepatic angiotensinogen production and may raise BP; progestin-only or non-hormonal methods should be considered in hypertensive women, or antihypertensive therapy should be intensified. Calcineurin inhibitors including cyclosporine and tacrolimus cause hypertension through renal vasoconstriction and sodium retention; amlodipine is the preferred CCB in this setting, as it is safe with calcineurin inhibitors, while diltiazem and verapamil should be avoided due to cytochrome P450 3A4 (CYP3A4) inhibition that raises calcineurin inhibitor levels. Sympathomimetics including OTC decongestants such as pseudoephedrine and phenylephrine raise BP through alpha-adrenergic vasoconstriction and may blunt antihypertensive therapy; intranasal corticosteroids should be substituted.
Resistant hypertension (RH) is defined as BP that remains above goal despite the concurrent use of three antihypertensive agents of different classes, one of which is a diuretic, at maximally tolerated doses.9,10 True resistant hypertension must be distinguished from pseudo-resistance, which is far more common. The most common cause of apparent resistance is medication non-adherence. Other causes include the white coat effect with elevated office but normal ambulatory BP, suboptimal drug doses with agents prescribed below the doses needed for adequate response, inadequate diuretic therapy with the wrong class or dose for the patient's renal function, drug interactions from NSAIDs, sympathomimetics, oral contraceptives, or calcineurin inhibitors, and inaccurate BP measurement due to technique error or improper cuff size. The prevalence of true resistant hypertension is approximately 10–12% of all hypertensive patients, rising to approximately 20–30% in specialty hypertension clinics.9 Patients with resistant hypertension have substantially higher rates of target organ damage, cardiovascular events, and chronic kidney disease progression than those with controlled hypertension.
Evaluation proceeds in four steps. The first step is to exclude pseudo-resistance: confirm medication adherence through pill count, urine drug levels, witnessed dosing, or drug level measurement; perform ambulatory BP monitoring (ABPM) or home BP monitoring (HBPM) to exclude white coat hypertension; review all medications for BP-raising drugs including NSAIDs, oral contraceptives, stimulants, decongestants, and vascular endothelial growth factor (VEGF) inhibitors; verify BP measurement technique and cuff appropriateness; and assess sodium intake using 24-hour urine sodium or dietary recall.
The second step is to optimize the current regimen: ensure the diuretic component is appropriate for the patient's renal function, with thiazide or thiazide-like agents for estimated glomerular filtration rate (eGFR) above 30 mL/min/1.73m² and a loop diuretic for eGFR below 30; ensure chlorthalidone or indapamide is used rather than HCTZ, as these provide superior 24-hour BP coverage; verify that each agent is at its maximum tolerated dose; and assess for and address volume overload through weight, edema assessment, and dietary adherence.
The third step is to screen for secondary causes. Secondary hypertension is found in 20–40% of truly resistant cases. Essential screening includes the aldosterone-to-renin ratio (ARR) for primary aldosteronism, plasma metanephrines for pheochromocytoma, renal artery imaging for renovascular hypertension, polysomnography for obstructive sleep apnea (OSA), thyroid-stimulating hormone (TSH), and cortisol. OSA is particularly common, present in approximately 80% of patients with resistant hypertension.9
The fourth step is to add a fourth agent. The PATHWAY-2 trial (2015) randomized 314 patients with true resistant hypertension in a crossover design to spironolactone 25–50 mg, bisoprolol 5–10 mg, doxazosin 4–8 mg, or placebo added to an existing three-drug regimen.11 Spironolactone produced the greatest home systolic BP reduction at 8.7 mmHg greater than placebo, significantly superior to both bisoprolol (4.5 mmHg greater than placebo) and doxazosin (4.0 mmHg greater than placebo). The effect was greatest in patients with the lowest plasma renin ratio, consistent with volume and aldosterone-dependent hypertension as the near-universal mechanism in resistant hypertension. Spironolactone 25–50 mg daily is therefore the evidence-based preferred fourth-line agent for resistant hypertension regardless of the ARR result.
If spironolactone is not tolerated due to gynecomastia or hyperkalemia, eplerenone 25–50 mg twice daily is the alternative selective MRA with no anti-androgenic effects, though it is somewhat less potent per milligram. If MRA therapy is contraindicated due to hyperkalemia or severe chronic kidney disease, amiloride 5–10 mg daily (epithelial sodium channel blockade with less hyperkalemia risk than MRAs), bisoprolol, or doxazosin are alternatives. If BP remains uncontrolled, oral minoxidil with mandatory beta-blocker and loop diuretic, or clonidine with caution regarding adherence, may be considered. A hyperkalemia management strategy of increasing importance involves potassium binders such as patiromer or sodium zirconium cyclosilicate, which can enable continued MRA use in patients with mild to moderate hyperkalemia (potassium 5.0–5.9 mEq/L with chronic kidney disease), maintaining renal and cardiovascular protection.
Renal denervation (RDN) is a catheter-based procedure delivering radiofrequency or ultrasound energy to the renal arteries, disrupting renal sympathetic nerves. The SYMPLICITY HTN-3 trial (2014), the first sham-controlled trial, found no reduction in ambulatory BP versus sham at 6 months.12 Subsequent trials including SPYRAL HTN-OFF MED and ON-MED (2017–2018) using improved catheter design showed significant BP reduction with RDN versus sham. The RADIANCE-HTN TRIO trial (2021) demonstrated BP reduction versus sham in patients with uncontrolled hypertension on standardized combination therapy. Renal denervation received FDA approval (Symplicity Spyral catheter) in 2023 for resistant hypertension in the United States and is emerging as an adjunct to pharmacotherapy in patients with true resistant or difficult-to-control hypertension, though it is not a replacement for optimal pharmacotherapy. Carotid baroreflex activation therapy (BAT) using electrical stimulation of carotid baroreceptors to increase afferent signaling and reduce central sympathetic outflow remains limited to specialist centers and is not widely available in routine practice.
Hypertensive urgency is defined as BP above 180/120 mmHg without evidence of acute target organ damage. The patient is asymptomatic or has only mild nonspecific symptoms such as headache or mild anxiety. Management involves oral antihypertensive therapy with the goal of BP reduction over 24–48 hours; this is not a medical emergency requiring hospitalization in the absence of target organ damage. A key principle is not to lower BP too rapidly, as this carries a risk of hypotensive injury to vulnerable organs, particularly in patients with pre-existing cerebrovascular disease or bilateral carotid stenosis. A practical approach is to ensure the patient is calm and resting, recheck BP after 30 minutes, use oral agents such as clonidine 0.2 mg, captopril 25 mg, or labetalol 200 mg, and arrange close follow-up within 24–72 hours.
Hypertensive emergency is defined as BP above 180/120 mmHg with evidence of acute target organ damage. It requires immediate intravenous therapy in an intensive care unit or monitored setting. The target is to reduce mean arterial pressure (MAP) by no more than 25% within the first hour, then to 160/100–110 mmHg over the next 2–6 hours, with further reduction toward target over 24–48 hours. Exceptions apply: in acute ischemic stroke, BP should not be lowered unless it is 220/120 mmHg or above (or above 185/110 mmHg if thrombolysis is planned); in aortic dissection, systolic BP should be reduced to 100–120 mmHg as rapidly as safely possible.
Hypertensive encephalopathy presents with headache, confusion, visual disturbances, and seizures, with posterior reversible encephalopathy syndrome (PRES) on MRI. The MAP reduction target is 20–25% in the first hour, and preferred agents are nicardipine IV, labetalol IV, or clevidipine IV.
Acute aortic dissection presents with severe tearing chest or back pain and a BP differential greater than 20 mmHg between arms. It is the most time-critical of all hypertensive emergencies. The target is systolic BP 100–120 mmHg and heart rate below 60 bpm as rapidly as safely possible. Beta-blockade must precede vasodilator therapy: esmolol IV (500 mcg/kg bolus then 50–200 mcg/kg/min) is initiated first to achieve heart rate control; a vasodilator such as sodium nitroprusside or nicardipine is then added if systolic BP remains above target. Administering a vasodilator first causes reflex tachycardia that increases the rate of aortic wall pressure rise (dP/dt), propagating dissection.
Acute coronary syndrome with hypertension is managed with beta-blockers for rate control and anti-ischemic effect, plus nitroglycerin for preload reduction and coronary vasodilation. Non-DHP CCBs are contraindicated in ST-elevation myocardial infarction (STEMI), and dihydropyridine CCBs used alone cause reflex tachycardia that increases myocardial oxygen demand.
In acute ischemic stroke, BP should not be lowered unless it is 220/120 mmHg or above, as elevated BP is often a protective response maintaining perfusion to the ischemic penumbra. If thrombolysis or mechanical thrombectomy is planned, BP should be maintained below 185/110 mmHg before the procedure and below 180/105 mmHg during and after treatment. Preferred agents are labetalol IV (5–10 mg over 1–2 minutes, repeated as needed) and nicardipine IV infusion.
Hypertensive emergency in pregnancy is defined as systolic BP of 160 mmHg or above or diastolic BP of 110 mmHg or above and requires treatment within 30–60 minutes to prevent maternal stroke and placental abruption. Preferred agents are IV labetalol (20 mg initial, then 40–80 mg every 10 minutes to a maximum of 300 mg), oral nifedipine immediate release (10–20 mg repeated as needed), and IV hydralazine (5–10 mg bolus repeated every 20 minutes). Magnesium sulfate is used for seizure prophylaxis in severe preeclampsia but is not an antihypertensive agent and does not lower BP. ACEi, ARBs, and sodium nitroprusside are contraindicated in pregnancy (nitroprusside carries risk of fetal cyanide toxicity). Detailed management of hypertension in pregnancy is covered in HTN-09.
Acute hypertensive heart failure with pulmonary edema requires combined afterload and preload reduction using IV nitroglycerin for venodilation, preload reduction, and coronary dilation; IV sodium nitroprusside for combined preload and afterload reduction; IV nicardipine for afterload reduction; and concurrent IV loop diuretics.
Medication non-adherence is the most common and most important modifiable cause of uncontrolled hypertension in clinical practice.1,2 Rates of non-adherence at one year range from 40–60% in most populations. Key strategies to improve adherence include using single-pill combinations, which produce a 20–30% improvement in adherence versus separate pills and should be used whenever clinically appropriate; simplifying the regimen through once-daily agents and minimization of pill burden; shared decision-making, as patients who understand their diagnosis and the rationale for treatment are more adherent; addressing adverse effects proactively, since many patients stop therapy silently due to side effects and should be asked about them at every visit; and using objective adherence monitoring when resistance is suspected, including urine or blood drug levels and electronic pill monitoring.
After initiating or changing therapy, BP should be rechecked at 2–4 weeks, sooner for high-risk patients or large dose changes. Once at target, BP should be rechecked every 3–6 months initially and annually once stably controlled. Home BP monitoring is recommended for most patients, as it improves treatment decisions and adherence. ABPM is indicated when white coat or masked hypertension is suspected, when office and home readings are discrepant, and after treatment changes in resistant hypertension.
The polypill concept involves a single pill containing a statin, ACEi, and aspirin. The TIPS trial (2009) demonstrated moderate reductions in BP and LDL cholesterol with a polypill in high-risk patients. The HOPE-3 trial (2016) showed that combined cholesterol and BP reduction in intermediate-risk patients reduced cardiovascular events. The SECURE trial (2022) found that polypill-based secondary prevention post-myocardial infarction significantly reduced major adverse cardiovascular events versus usual care.13 The polypill concept has greatest utility in resource-limited settings and in secondary prevention where adherence to multiple separate medications is the major barrier.
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127–e248.
doi:10.1016/j.jacc.2017.11.006Mancia G, Kreutz R, Brunstrom M, et al. 2023 ESH guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874–2071.
doi:10.1097/HJH.0000000000003480Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967.
doi:10.1016/S0140-6736(15)01225-8Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure (DASH). N Engl J Med. 1997;336(16):1117–1124.
doi:10.1056/NEJM199704173361601Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients (ACCOMPLISH). N Engl J Med. 2008;359(23):2417–2428.
doi:10.1056/NEJMoa0806182ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic (ALLHAT). JAMA. 2002;288(23):2981–2997.
doi:10.1001/jama.288.23.2981SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control (SPRINT). N Engl J Med. 2015;373(22):2103–2116.
doi:10.1056/NEJMoa1511939Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events (ONTARGET). N Engl J Med. 2008;358(15):1547–1559.
doi:10.1056/NEJMoa0801317Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. Hypertension. 2008;51(6):1403–1419.
doi:10.1161/HYPERTENSIONAHA.108.189141Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management. Hypertension. 2018;72(5):e53–e90.
doi:10.1161/HYP.0000000000000084Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2). Lancet. 2015;386(10008):2059–2068.
doi:10.1016/S0140-6736(15)00257-3Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension (SYMPLICITY HTN-3). N Engl J Med. 2014;370(15):1393–1401.
doi:10.1056/NEJMoa1402670Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill strategy in secondary cardiovascular prevention (SECURE). N Engl J Med. 2022;387(11):967–977.
doi:10.1056/NEJMoa2208275Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (FIDELIO-DKD). N Engl J Med. 2020;383(23):2219–2229.
doi:10.1056/NEJMoa2025845McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure (PARADIGM-HF). N Engl J Med. 2014;371(11):993–1004.
doi:10.1056/NEJMoa1409077